Join to learn about the latest updates and controversies including the utility of immunotherapy as a first-line treatment and in earlier disease states, the management of side-effects, treatment eligibility, the mechanisms-of-action, CAR-T cell therapy in prostate cancer, the global BCG shortage and the immune-mediated abscopal effect in radiotherapy. Challenging cases will be discussed by a multidisciplinary meeting panel.
Convened by Associate Professor Niall Corcoran, VCCC Research & Education Lead in GU Cancers the objectives for this symposium include:
- to bring the latest treatment evidence to the forum for discussion
- to share learnings from the management of new treatments (toxicities, timings, adoption)
- to identify areas to work on collectively to address some of the unanswered immune-oncology questions
Dr Peter Black
Senior Research Scientist, Vancouver Prostate Centre
Professor, Department of Urologic Sciences, University of British Columbia
Dr Peter Black is a urologist based at the Vancouver Prostate Centre in Canada. Dr Black trained with one of the premier bladder cancer research groups in the world at M.D. Anderson Cancer Center in Houston, Texas, and has now established a research group at the Prostate Centre focused on targeting growth factor receptors in urothelial carcinoma of the bladder. Dr. Black is a consultant/adviser to GenomeDx Biosciences, Janssen, Astellas, Amgen, Sitka, AbbVie, Bristol Myers Squibb, Bayer, Biosyent, Sanofi, Urogen, and Roche/Genentech. He is a key opinion leader in the field of immunotherapy in GU cancers.
Program will be available soon